Ed Kaye, Stoke Therapeutics CEO

Stoke Ther­a­peu­tics un­veils more da­ta on stud­ies of Dravet drug, hint­ing at im­prove­ments to cog­ni­tion and be­hav­ior

Stoke Ther­a­peu­tics pre­sent­ed more da­ta on its in­ves­ti­ga­tion­al Dravet syn­drome treat­ment on Tues­day morn­ing, say­ing it helped re­duce seizures and im­prove cer­tain cog­ni­tive and be­hav­ioral func­tions, but the 45 mg da­ta were well be­low an­a­lyst ex­pec­ta­tions and in­vestors sent the stock $STOK down near­ly 40% be­fore the open­ing bell.

It’s still a lim­it­ed look at the stud­ies, though, and more da­ta are need­ed from two open-la­bel Phase I/IIa tri­als and an ex­ten­sion study be­fore fi­nal­iz­ing Phase III plans next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.